Diamond Pharma Services' acquisition strengthens pharmacovigilance division

27 Apr 2020

The acquisition will enhance senior-level expertise, which will support clients from Diamond’s regulatory affairs business in specialist areas such as gene and cell therapies.

Diamond PV Services, the pharmacovigilance division of Diamond Pharma Services, has acquired PharmaCentral, an innovative pharmacovigilance services and medical affairs business based in Dublin, Ireland.

Diamond Pharma Services' acquisition strengthens pharmacovigilance division

The acquisition will expand Diamond’s presence in Europe and enhance the senior-level expertise within its pharmacovigilance team.

PharmaCentral offers a wide range of pharmacovigilance consultancy services, based on a wealth of experience in pharmacovigilance and medical affairs in both pharma and CRO environments. The acquisition of PharmaCentral forms part of Diamond’s growth strategy for its pharmacovigilance division, which has achieved a Compound Annual Growth Rate (CAGR) in revenues of 27% over the last 3 years. This rapid expansion of Diamond’s pharmacovigilance senior-level team is required to support clients from Diamond’s regulatory affairs business in specialist areas such as gene and cell therapies.

Diamond Pharma Services provides regulatory affairs, pharmacovigilance and compliance & quality services to support pharmaceutical and biotechnology companies in obtaining and maintaining medicinal product licences throughout all stages of a product’s lifecycle. Diamond will continue to expand its presence in Dublin through 2020, with recruitment across all three of its divisions.

David Boyd, Managing Director, Diamond PV Services, said: “We have seen strong organic growth over the last 3 years, which has driven us to evaluate our resources, including our in-house expertise, processes and systems. This acquisition will help support the next phase of growth, representing a step change in our senior team.”

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more